Fig. 8 | Scientific Reports

Fig. 8

From: ABCE1 facilitates tumour progression via aerobic glycolysis and inhibits cell death in human colorectal cancer cells through the p53 signalling pathway

Fig. 8

ABCE1 plays an oncogenic role in colorectal cancer cells. (A) GSEA plots from Wiki pathway shows the involvement of ABCE1 in Integrated cancer pathway. (B) The heatmap illustration mentioned the ABCE1 expression levels (TPM) among various colon cancer cell lines. (C) Chemical structure of irinotecan. (D) MTT assay for cell viability shows the increasing concentration of irinotecan (10–100µM) for 24–48 h intervals in NCM-460, HCT-116, and HT-29 cells. IC50 values were calculated using Graphpad prism software. IC50 concentration value of irinotecan for 48 h (HCT-116: 53.98µM; HT-29: 39.17µM) was followed for further experiments. (E) Cell viability by MTT assay was examined by pre-treating with glycolytic inhibitor, 2DG (4 mM and 8 mM) along with irinotecan in HCT-116 and HT-29 cells. (F) GSEA plots represents the role of glycolysis and metabolic reprogramming in colon cancer from GSE33113 dataset. (G and H) The glucose uptaken and lactose production was examined by treating irinotecan in HCT-116 and HT-29 cells. (I and J) The cellular catalase (CAT) and Superoxide Dismutase (SOD) was measured comparing untreated and irinotecan treated in HCT-116 and HT-29 cells. Statistical significance: *p < 0.05, **p < 0.001, and ***p < 0.0001.

Back to article page